Declared Dividend • Apr 27
Dividend of €1.27 announced Shareholders will receive a dividend of €1.27. Ex-date: 10th June 2026 Payment date: 12th June 2026 Dividend yield will be 2.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 21% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 25% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Annuncio • Apr 25
Clínica Baviera, S.A., Annual General Meeting, May 27, 2026 Clínica Baviera, S.A., Annual General Meeting, May 27, 2026. Location: paseo de la castellana 20, madrid., Spain Reported Earnings • Mar 05
Full year 2025 earnings released: EPS: €2.58 (vs €2.51 in FY 2024) Full year 2025 results: EPS: €2.58 (up from €2.51 in FY 2024). Revenue: €304.9m (up 15% from FY 2024). Net income: €42.1m (up 4.6% from FY 2024). Profit margin: 14% (down from 15% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Feb 09
Now 23% undervalued Over the last 90 days, the stock has risen 32% to €53.00. The fair value is estimated to be €68.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 12%. New Risk • Feb 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (4.4% average weekly change). Reported Earnings • Dec 01
Third quarter 2025 earnings released: EPS: €0.34 (vs €0.29 in 3Q 2024) Third quarter 2025 results: EPS: €0.34 (up from €0.29 in 3Q 2024). Revenue: €65.3m (up 17% from 3Q 2024). Net income: €5.49m (up 19% from 3Q 2024). Profit margin: 8.4% (up from 8.2% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Nov 27
Now 20% overvalued Over the last 90 days, the stock has fallen 2.4% to €44.80. The fair value is estimated to be €37.28, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%. Buy Or Sell Opportunity • Sep 08
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 4.9% to €45.00. The fair value is estimated to be €37.34, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%. Buy Or Sell Opportunity • Aug 21
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 17% to €45.00. The fair value is estimated to be €37.34, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%. Buy Or Sell Opportunity • Aug 05
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 20% to €45.20. The fair value is estimated to be €37.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 12%. Reported Earnings • Jul 31
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: €75.9m (up 14% from 2Q 2024). Net income: €9.45m (down 14% from 2Q 2024). Profit margin: 13% (down from 17% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Jul 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (4.5% average weekly change). Buy Or Sell Opportunity • Jun 27
Now 23% undervalued Over the last 90 days, the stock has risen 11% to €39.90. The fair value is estimated to be €51.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 13%. Upcoming Dividend • Jun 04
Upcoming dividend of €1.27 per share Eligible shareholders must have bought the stock before 11 June 2025. Payment date: 13 June 2025. Payout ratio is a comfortable 64% and this is well supported by cash flows. Trailing yield: 3.7%. Lower than top quartile of Spanish dividend payers (4.9%). Higher than average of industry peers (2.3%). Buy Or Sell Opportunity • May 28
Now 21% undervalued Over the last 90 days, the stock has risen 16% to €38.70. The fair value is estimated to be €48.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 13%. Annuncio • Apr 25
Clínica Baviera, S.A., Annual General Meeting, May 27, 2025 Clínica Baviera, S.A., Annual General Meeting, May 27, 2025. Location: paseo de la castellana 20, madrid Spain Annuncio • Apr 04
Clínica Baviera, S.A. has filed a Follow-on Equity Offering. Clínica Baviera, S.A. has filed a Follow-on Equity Offering.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,304,606
Transaction Features: Subsequent Direct Listing Reported Earnings • Nov 26
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: €56.0m (up 20% from 3Q 2023). Net income: €4.59m (down 23% from 3Q 2023). Profit margin: 8.2% (down from 13% in 3Q 2023). The decrease in margin was driven by higher expenses. New Risk • Nov 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 5.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.4% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €32.70, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 18x in the Healthcare industry in Europe. Total returns to shareholders of 103% over the past three years. New Risk • Sep 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 5.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.2% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Jul 28
First half 2024 earnings released: EPS: €1.44 (vs €1.29 in 1H 2023) First half 2024 results: EPS: €1.44 (up from €1.29 in 1H 2023). Revenue: €133.0m (up 14% from 1H 2023). Net income: €23.4m (up 12% from 1H 2023). Profit margin: 18% (in line with 1H 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Jul 09
Upcoming dividend of €1.27 per share Eligible shareholders must have bought the stock before 16 July 2024. Payment date: 18 July 2024. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 5.4%. Lower than top quartile of Spanish dividend payers (5.5%). Higher than average of industry peers (2.2%). Reported Earnings • Mar 04
Full year 2023 earnings released Full year 2023 results: Revenue: €224.9m (up 13% from FY 2022). Net income: €36.7m (up 24% from FY 2022). Profit margin: 16% (up from 15% in FY 2022). The increase in margin was driven by higher revenue. Reported Earnings • Nov 27
Third quarter 2023 earnings released Third quarter 2023 results: EPS: €0.36. Revenue: €46.9m (up 12% from 3Q 2022). Net income: €5.93m (up 18% from 3Q 2022). Profit margin: 13% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 27
First half 2023 earnings released First half 2023 results: EPS: €1.29. Revenue: €116.7m (up 13% from 1H 2022). Net income: €21.0m (up 9.6% from 1H 2022). Profit margin: 18% (in line with 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 26% per year. Upcoming Dividend • May 24
Upcoming dividend of €0.65 per share at 6.9% yield Eligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 6.9%. Within top quartile of Spanish dividend payers (6.1%). Higher than average of industry peers (2.4%). Reported Earnings • Mar 02
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: €1.81 (up from €1.68 in FY 2021). Revenue: €198.4m (up 14% from FY 2021). Net income: €29.5m (up 7.8% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.5%. Revenue is forecast to grow 5.8% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Dec 07
Upcoming dividend of €0.41 per share Eligible shareholders must have bought the stock before 14 December 2022. Payment date: 16 December 2022. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 5.6%. Lower than top quartile of Spanish dividend payers (5.8%). Higher than average of industry peers (3.0%). Price Target Changed • Nov 16
Price target decreased to €24.30 Down from €29.00, the current price target is provided by 1 analyst. New target price is 34% above last closing price of €18.10. Stock is down 11% over the past year. The company is forecast to post earnings per share of €1.80 for next year compared to €1.68 last year. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Isabel Navarro was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Jul 28
Second quarter 2022 earnings released: EPS: €0.49 (vs €0.51 in 2Q 2021) Second quarter 2022 results: EPS: €0.49 (down from €0.51 in 2Q 2021). Revenue: €50.5m (up 11% from 2Q 2021). Net income: €8.04m (down 2.5% from 2Q 2021). Profit margin: 16% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 2.1%, compared to a 6.2% growth forecast for the industry in Spain. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • May 18
Upcoming dividend of €0.43 per share Eligible shareholders must have bought the stock before 25 May 2022. Payment date: 27 May 2022. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 4.4%. Lower than top quartile of Spanish dividend payers (5.5%). Higher than average of industry peers (2.4%). Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Isabel Navarro was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 15
Full year 2021 earnings released: EPS: €1.68 (vs €0.85 in FY 2020) Full year 2021 results: EPS: €1.68 (up from €0.85 in FY 2020). Revenue: €173.2m (up 41% from FY 2020). Net income: €27.4m (up 97% from FY 2020). Profit margin: 16% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.9%, compared to a 6.8% growth forecast for the industry in Spain. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 03
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: €1.68 (up from €0.85 in FY 2020). Revenue: €173.2m (up 41% from FY 2020). Net income: €27.4m (up 97% from FY 2020). Profit margin: 16% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Dec 14
Upcoming dividend of €0.41 per share Eligible shareholders must have bought the stock before 21 December 2021. Payment date: 23 December 2021. Payout ratio is a comfortable 49% but the company is not cash flow positive. Trailing yield: 2.5%. Lower than top quartile of Spanish dividend payers (5.2%). Higher than average of industry peers (2.0%). Valuation Update With 7 Day Price Move • Sep 15
Investor sentiment improved over the past week After last week's 15% share price gain to €20.60, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 26x in the Healthcare industry in Europe. Total returns to shareholders of 66% over the past three years. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment improved over the past week After last week's 38% share price gain to €20.00, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 31x in the Healthcare industry in Europe. Total returns to shareholders of 52% over the past three years. Upcoming Dividend • May 19
Inaugural dividend of €0.45 per share Eligible shareholders must have bought the stock before 26 May 2021. Payment date: 28 May 2021. The company last paid an ordinary dividend in April 2019. The average dividend yield among industry peers is 1.7%. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improved over the past week After last week's 20% share price gain to €15.10, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 29x in the Healthcare industry in Europe. Total returns to shareholders of 22% over the past three years. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 17% share price gain to €13.60, the stock is trading at a trailing P/E ratio of 25.4x, up from the previous P/E ratio of 21.7x. This compares to an average P/E of 26x in the Healthcare industry in Europe. Total returns to shareholders over the past three years are 67%. Is New 90 Day High Low • Dec 16
New 90-day high: €12.00 The company is up 36% from its price of €8.80 on 17 September 2020. The Spanish market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 1.0% over the same period. Is New 90 Day High Low • Nov 16
New 90-day high: €9.40 The company is up 4.0% from its price of €9.00 on 18 August 2020. The Spanish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is up 1.0% over the same period. Is New 90 Day High Low • Oct 14
New 90-day low: €8.30 The company is down 13% from its price of €9.55 on 16 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 2.0% over the same period. Is New 90 Day High Low • Sep 25
New 90-day low: €8.75 The company is down 10.0% from its price of €9.70 on 26 June 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 4.0% over the same period.